http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103599083-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2013-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103599083-B |
| titleOfInvention | Levo-oxiracetam slow-release tablet and preparation method thereof |
| abstract | A kind of take levo-oxiracetam as the levo-oxiracetam slow-release tablet of primary raw material, be made up of the supplementary material of following weight proportion: a kind of slow releasing tablet of levo-oxiracetam, it is characterized in that, this slow releasing tablet comprises levo-oxiracetam 1 part, sustained-release matrix material 0.8 ~ 1.2 part, fluidizer 0.06 ~ 0.12 part, lubricant 0.02 ~ 0.05 part, the antiplastering aid 0.02 ~ 0.05 part of weighing scale, binding agent 1 ~ 1.5 part.Levo-oxiracetam slow-release tablet of the present invention is a kind of slow releasing tablet being used for the treatment of brain injury and the neurological deficit caused, memory and disturbance of intelligence, its any surface finish, and its principal agent levo-oxiracetam release behavior meets the requirement of slow releasing tablet after testing; Simultaneously principal agent levo-oxiracetam of the present invention becomes slow releasing, thus this product comparatively conventional formulation can reduce and take number of times; This product principal agent levo-oxiracetam slow releasing, can provide steady, lasting effective blood drug concentration, avoids or reduces blood drug level peak valley phenomenon, is conducive to the safety improving drug use, reduces adverse effect. |
| priorityDate | 2013-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.